← Back to Screener
Century Therapeutics, Inc. Common Stock (IPSC)
Price$2.34
Favorite Metrics
Price vs S&P 500 (26W)348.44%
Price vs S&P 500 (4W)-2.06%
Market Capitalization$467.28M
All Metrics
Book Value / Share (Quarterly)$1.82
P/TBV (Annual)0.70x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)175.86%
Cash Flow / Share (Quarterly)$-1.20
Price vs S&P 500 (YTD)157.22%
Net Profit Margin (TTM)-18.92%
EPS (TTM)$-0.11
10-Day Avg Trading Volume1.41M
EPS Excl Extra (TTM)$-0.11
EPS (Annual)$-0.11
ROI (Annual)-6.03%
Cash / Share (Quarterly)$1.34
ROA (Last FY)-4.28%
Revenue Growth TTM (YoY)1556.51%
EBITD / Share (TTM)$-0.04
ROE (5Y Avg)-45.18%
Operating Margin (TTM)-28.63%
Cash Flow / Share (Annual)$-1.20
P/B Ratio2.94x
P/B Ratio (Quarterly)0.55x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.53x
Net Interest Coverage (TTM)-90.50x
ROA (TTM)-3.58%
EPS Incl Extra (Annual)$-0.11
Current Ratio (Annual)5.97x
Quick Ratio (Quarterly)5.79x
3-Month Avg Trading Volume1.75M
52-Week Price Return420.00%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.43
P/S Ratio (Annual)4.28x
Asset Turnover (Annual)0.49x
52-Week High$3.04
EPS Excl Extra (Annual)$-0.11
CapEx CAGR (5Y)-43.36%
26-Week Price Return357.18%
Quick Ratio (Annual)5.83x
13-Week Price Return28.71%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.97x
Enterprise Value$405.426
Asset Turnover (TTM)0.31x
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-8.84%
Cash / Share (Annual)$1.34
3-Month Return Std Dev102.09%
Net Income / Employee (TTM)$-0
ROE (Last FY)-6.03%
Net Interest Coverage (Annual)-93.52x
EPS Basic Excl Extra (Annual)$-0.11
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.11
ROI (TTM)-4.87%
P/S Ratio (TTM)4.07x
Revenue / Share (Annual)$1.26
Tangible BV / Share (Annual)$1.43
Price vs S&P 500 (52W)384.91%
Year-to-Date Return161.36%
5-Day Price Return14.54%
EPS Normalized (Annual)$-0.11
ROA (5Y Avg)-25.36%
Net Profit Margin (Annual)-8.78%
Month-to-Date Return15.04%
Cash Flow / Share (TTM)$-1.98
EBITD / Share (Annual)$-0.04
Operating Margin (Annual)-15.82%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-44.78%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.11
P/TBV (Quarterly)0.70x
P/B Ratio (Annual)0.55x
Pretax Margin (TTM)-17.38%
Book Value / Share (Annual)$1.82
Price vs S&P 500 (13W)25.85%
Beta1.67x
Revenue / Share (TTM)$1.25
ROE (TTM)-4.87%
52-Week Low$0.43
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IPSCCentury Therapeutics, Inc. Common Stock | 4.07x | 1556.51% | — | — | $2.34 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Century Therapeutics develops allogeneic cell therapies for cancer, autoimmune, and inflammatory diseases using CRISPR-engineered stem cells and proprietary immune-evasion technology. The company's platform overcomes key limitations of first-generation cell therapies by reducing immune rejection and simplifying manufacturing. This approach enables faster development cycles, improved scalability, and reduced supply chain risks.